Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients
| العنوان: | Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients |
|---|---|
| المؤلفون: | Lu Si, Chuanliang Cui, Xuan Wang, Lili Mao, Bixia Tang, Xinan Sheng, Bin Lian, Jun Guo, Zhihong Chi, Yan Kong, Xieqiao Yan |
| المصدر: | Thoracic Cancer Thoracic Cancer, Vol 10, Iss 4, Pp 950-956 (2019) |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Male, medicine.medical_specialty, Esophageal Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Antineoplastic Agents, lcsh:RC254-282, Adjuvant therapy, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Drug Therapy, Internal medicine, medicine, Humans, Molecular Targeted Therapy, Esophagus, Melanoma, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, business.industry, melanoma of esophagus, Cancer, General Medicine, Immunotherapy, Original Articles, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Survival Analysis, 030104 developmental biology, medicine.anatomical_structure, Treatment Outcome, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Cohort, Female, Original Article, immunotherapy, business |
| الوصف: | BACKGROUND Primary malignant melanoma of the esophagus (PMME) is rare. Patients with advanced melanoma of esophageal origin tend to have lower response rates to traditional therapies than those with other melanomas. We report our experience of 12 patients with PMME administered PD-1 inhibitors. METHODS This is a retrospective analysis of the clinical data of 76 patients with PMME who attended Peking University Cancer Hospital between January 2008 and September 2017. Objective response rates (ORRs) and progression-free survival (PFS) were assessed. RESULTS The 76 PMMEs were classified as unresectable or metastatic. The patients were allocated to three cohorts according to their treatment: chemotherapy (C: 46 patients), targeted therapy (T: 2 patients), and PD-1 inhibitors (IT: 12 patients). The PFS in the C cohort was three months with a limited ORR of 10.9%. In the IT cohort, seven patients (75.0%) achieved a partial response and three had stable disease for 4+ months. The median PFS in the IT cohort was not reached and the mean was 15.6 months, which was much longer than in cohort C (P |
| تدمد: | 1759-7714 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::669bf5646d0bfabf9b0d04ce19f1388eTest https://pubmed.ncbi.nlm.nih.gov/30864295Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....669bf5646d0bfabf9b0d04ce19f1388e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17597714 |
|---|